Compare Stocks → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:KTOVNASDAQ:NRBONASDAQ:OBSVNASDAQ:OTICNASDAQ:PHAS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKTOVPurple Biotech$0.53-3.6%$4.16$2.20▼$14.40$8.32M2.371.18 million shs111,878 shsNRBONeuroBo Pharmaceuticals$4.00+1.5%$4.15$2.89▼$6.75$19.28M-0.23938,559 shs35,344 shsOBSVObsEva$0.01$0.08▼$2.14$156K0.688.94 million shsN/AOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/APHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shsN/AThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKTOVPurple Biotech0.00%+1.61%-23.12%-32.96%-70.76%NRBONeuroBo Pharmaceuticals+1.65%+7.10%+13.17%-12.39%-16.76%OBSVObsEva0.00%+900.00%-60.00%-96.36%-97.62%OTICOtonomy0.00%0.00%0.00%0.00%0.00%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%+42.86%“Crash Insurance” For Your Retirement (Ad)When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKTOVPurple BiotechN/AN/AN/AN/AN/AN/AN/AN/ANRBONeuroBo Pharmaceuticals2.5777 of 5 stars3.55.00.00.02.50.00.6OBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKTOVPurple BiotechN/AN/AN/AN/ANRBONeuroBo Pharmaceuticals3.00Buy$10.00150.31% UpsideOBSVObsEvaN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest OTIC, OBSV, KTOV, NRBO, and PHAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2024NRBONeuroBo PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKTOVPurple Biotech$1M8.32N/AN/A$5.56 per share0.10NRBONeuroBo PharmaceuticalsN/AN/AN/AN/A$3.44 per shareN/AOBSVObsEva$20.11M0.00N/AN/A$0.41 per share0.00OTICOtonomy$130K4.48N/AN/A$0.97 per share0.01PHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKTOVPurple Biotech-$5.85M-$3.00N/AN/AN/AN/AN/AN/AN/ANRBONeuroBo Pharmaceuticals-$12.47MN/A0.00N/AN/AN/A-59.42%-45.40%5/10/2024 (Estimated)OBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/AOTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/APHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKTOVPurple BiotechN/AN/AN/AN/AN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKTOVPurple BiotechN/A2.22N/ANRBONeuroBo PharmaceuticalsN/A3.783.78OBSVObsEvaN/A0.610.61OTICOtonomyN/A1.741.74PHASPhaseBio PharmaceuticalsN/A0.470.47OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKTOVPurple Biotech30.72%NRBONeuroBo Pharmaceuticals1.37%OBSVObsEva17.52%OTICOtonomy41.23%PHASPhaseBio Pharmaceuticals49.02%Insider OwnershipCompanyInsider OwnershipKTOVPurple Biotech2.98%NRBONeuroBo Pharmaceuticals0.54%OBSVObsEva14.40%OTICOtonomy1.09%PHASPhaseBio Pharmaceuticals9.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableKTOVPurple Biotech915.73 millionN/ANot OptionableNRBONeuroBo Pharmaceuticals84.91 million4.88 millionNot OptionableOBSVObsEva4877.97 million66.74 millionNot OptionableOTICOtonomy5168.53 million67.78 millionOptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableOTIC, OBSV, KTOV, NRBO, and PHAS HeadlinesSourceHeadlineModified Release Neurology Therapeutics Report 202…pharmiweb.com - February 19 at 2:09 PMVelia Therapeutics Appoints Michael York as Chief Business Officerfinance.yahoo.com - December 14 at 8:55 AMLeading innovators in GLP-1 analogues for the pharmaceutical industrypharmaceutical-technology.com - November 6 at 7:00 AMAlcami Announces CEO Transitionfinance.yahoo.com - June 5 at 10:33 AM8-K: PhaseBio Pharmaceuticals Incmarketwatch.com - May 12 at 2:46 AMAbsci Corporation: Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Resultsfinanznachrichten.de - March 31 at 6:59 PMBioCryst Pharmaceuticals, Inc.: BioCryst Appoints Dr. Nancy Hutson as Chair of the Boardfinanznachrichten.de - March 31 at 1:59 PMBioCryst Appoints Dr. Nancy Hutson as Chair of the Boardfinance.yahoo.com - March 31 at 8:59 AMCardiomyopathy Medication Market Size and Forecast till 2031marketwatch.com - March 22 at 1:16 PMCardiomyopathy Medication Market Emerging Demand and Drive Growth by 2028 with Top Countries Datamarketwatch.com - February 28 at 1:24 PMJi Xing obtains global rights to cardiovascular candidate from Phasebiobioworld.com - February 9 at 7:59 AMBankrupt PhaseBio settles with investor-partner, handing off late-stage drugendpts.com - January 18 at 11:29 PMSFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio Pharmaceuticalsbenzinga.com - January 17 at 12:24 PMBankruptcy court approves PhaseBio's $32.9M asset transfer dealbizjournals.com - January 5 at 7:47 PMBankrupt PhaseBio Identifies Chiesi as Lead Bidder for Bentracimab Assetsmarketwatch.com - November 8 at 12:22 AMShort Volatility Alert: PhaseBio Pharmaceuticals, Inc.benzinga.com - November 4 at 2:57 PMWhy Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Sessionmsn.com - November 2 at 6:43 PMWhy Goodyear Tire & Rubber Shares Are Trading Lower; Here Are 24 Stocks Moving Premarketmsn.com - November 1 at 12:30 PMPhaseBio Pharmaceuticals 10% Owner Trades Company's Stockbenzinga.com - October 27 at 4:54 PMPhaseBio Files for Bankruptcy Following Blackstone-Backed Partner’s Lawsuitwsj.com - October 25 at 5:37 AMPhaseBio files for bankruptcy, has a potential deal to sell its assets for up to $100Mbizjournals.com - October 25 at 5:37 AMPhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code (Businesswire)avanza.se - October 24 at 12:07 PMAs top investor makes its play to grab lead drug, PhaseBio counters with Chapter 11, stalking-horse bidendpts.com - October 24 at 12:07 PMPhaseBio Pharma Files For Chapter 11 Bankruptcy Protectionnasdaq.com - October 24 at 12:07 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Intuitive Surgical Leads the Robotic Surgery MovementApril 22, 2024 6:10 AMView Intuitive Surgical Leads the Robotic Surgery Movement3 Computer Vision Stocks for Long-Term Gains From AIApril 16, 2024 6:08 AMView 3 Computer Vision Stocks for Long-Term Gains From AICan Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?April 10, 2024 7:55 AMView Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?All Headlines Company DescriptionsPurple BiotechNASDAQ:KTOVPurple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.NeuroBo PharmaceuticalsNASDAQ:NRBONeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.ObsEvaNASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.OtonomyNASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.PhaseBio PharmaceuticalsNASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.